Divalproex Sodium Tablet, Extended Release
Product Images NDC 50268-260

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50268-260). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

50 (259 15)

This is a packaging label for Divalproex Sodium Extended-release Tablets USP, 250 mg strength, manufactured by AvPAK. The label indicates Rx only, and the package contains 50 tablets (5 x 10) unit dose. The label highlights once-daily dosing and mentions valproic acid activity. Storage instructions and a QR code are also present.*

FDA Label Image

30 (260 13)

Label for Divalproex Sodium Extended-release Tablets, USP, 500 mg oral tablets by AvPAK. The label indicates a once-daily dosing with 30 tablets per package (3 x 10). It includes storage instructions, dosing information, and a barcode with NDC 50268-260-13.*

FDA Label Image

10 (Divalproex Sodium Extended Release Tablets Usp 1)

Chemical structure diagram of divalproex sodium, showing the molecular arrangement with sodium and multiple carbon chains.*

FDA Label Image

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)

A line graph comparing the percentage reduction in clinical parameter score (CPS) rate between Divalproex Sodium and placebo across a percentage of patients. The vertical axis shows percentage change in CPS rate from worsening to improvement, while the horizontal axis shows the percentage of patients from 100% to 0%. Two curves represent patient outcomes for Divalproex Sodium and placebo.*

FDA Label Image

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)

A line graph showing the percentage reduction in CPS rate plotted against the percentage of patients for Divalproex Sodium. Two curves represent high dose (solid line) and low dose (dashed line) treatments. The vertical axis indicates improvement or worsening in CPS rate, with positive values showing improvement and negative values indicating worsening.*

FDA Label Image

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

Bar chart comparing Placebo and Divalproex Sodium Extended Release groups. The y-axis appears to represent a measured variable ranging from 0 to 1.2. The Divalproex Sodium Extended Release group has a higher bar (approximately 1.2) compared to the Placebo (approximately 0.6), with a noted p-value of 0.006 indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.